1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is 21,45€ (+211,77%). The median is 21,45€ (+211,77%).
| Buy |
9 |
| Hold |
2 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 30.25m | 38,76% |
| Gross profit | 30.25m | 2.924,77% |
| Net profit | −481.92k | 97,97% |
| EBITDA | 13.31m | 215,75% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 298.75m€ |
Number of shares | 41.64m |
52-week high/low | 7,59€ - 2,33€ |
| Dividends | No |
Beta | 1,55 |
P/E ratio | 3,08 |
PEG ratio | 0,00 |
P/B ratio | −1,74 |
P/S ratio | 2,62 |
Company profile
| Name | Agenus Inc. |
| CEO | Garo H. Armen |
| Headquarters | Lexington,
ma USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| Employees | 81 |
Deep Dive
Discover assets
Shareholders of Agenus Inc. also invest in the following assets
